| abstract |
The present invention provides compounds which are agonists of the progesterone receptor and have structures (I) or (II) wherein R1 and R2 are independent substituents selected from the group of H, optionally substituted Cl to C6 alkyl, alkenyl, alkynyl, or alkynyl groups C3 to C8 cycloalkyl, aryl, substituted aryl, or heterocyclic groups, or CORA or NR B COR A; or RI and R2 are fused to form an optionally substituted 3 to 8 membered Spiro cyclic alkyl or alkenyl ring or a Spiro cyclic ring containing one to three heteroatoms selected from O, S and N; R A is selected from H, amino, or optionally substituted C1 to C3 alkyl, aryl, Cl to C3 alkoxy, or Cl to C3 aminoalkyl groups; R B is H, C1 to C3 alkyl, or substituted C1 to C3 alkyl; R3 is H, OH, NH2 COR C, or optionally substituted C1 to C6 alkyl, C3 to C6 alkenyl, or alkynyl groups; R C is selected from H or optionally substituted Cl to C3 alkyl, aryl, Cl to C3 alkoxy, or Ci to C3 aminoalkyl groups; Q1 is S, NR7; or CR8R9, R5 is an optionally trisubstituted benzene ring or an optionally substituted five or six membered heterocyclic ring with 1, 2, or 3 ring heteroatoms selected from the group of O, S, SO, SO2 or NR6; or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds for contraception and the treatment of progesterone-related maladies. |